跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SOLIFENACINA /TAMSULOSINA AUROVITAS 6 MG/0,4 MG COMPRIMIDOS DE LIBERACION MODIFICADA EFG - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
SOLIFENACINA /TAMSULOSINA AUROVITAS 6 MG/0,4 MG COMPRIMIDOS DE LIBERACION MODIFICADA EFG
Approved
STANDARD
SOLIFENACINA /TAMSULOSINA AUROVITAS 6 MG/0,4 MG COMPRIMIDOS DE LIBERACION MODIFICADA EFG
Aurovitas Spain, S.A.U.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 19, 2023
Approval ID
b36879b089c2b866
Company
Aurovitas Spain, S.A.U.
Type
Standard
Approval Details
Approval Id
b36879b089c2b866
Drug Cima Aemps Name
SOLIFENACINA /TAMSULOSINA AUROVITAS 6 MG/0,4 MG COMPRIMIDOS DE LIBERACION MODIFICADA EFG
Register Number
88915
Holder Company Name
Aurovitas Spain, S.A.U.
Marketing Company Name
Aurovitas Spain, S.A.U.
Authorization Date
2023-06-19
Dosage Form
COMPRIMIDO DE LIBERACIÓN MODIFICADA
Dose
6 mg/0,4 mg
Route Of Administration
VÍA ORAL
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
Yes
Company Name
Aurovitas Spain, S.A.U.
Active Ingredients
SOLIFENACINA SUCCINATO
6 mg
TAMSULOSINA HIDROCLORURO
0,4 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 19, 2023
Approval ID
b36879b089c2b866
Type
Standard
Back to CIMA-AEMPS Approvals